Transforming cancer
treatment with Protein Phosphatase 2A inhibitors
Unveiling the first of a novel class of therapeutic agents
Bas van der Baan, CEO
1 | Website | November 20, 2023 |
Forward looking statements
This information packet contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to obtain and maintain compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at www.sec.gov.
Readers are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
2 | website | November 20, 2023 |
Chemotherapy & Immunotherapy:
Shared potential, common challenges
Broad Applicability | Limited Efficacy | Safety Risks | ||
Intrinsic and acquired | Toxicity limits treatment | |||
Applicable to different | ||||
resistance to therapy | dosage and duration, | |||
tumor types and stages. | ||||
limits its impact. | affecting efficacy. | |||
3 | Website | November 20, 2023 |
Our unique approach:
enhance existing therapies with PP2A inhibitors
Pre-Clinical Evidence: LB-100 is a first-in-class enhancer of chemotherapy and immunotherapy
4 | Website | November 20, 2023 |
LB-100
5 | Website | November 20, 2023 |
LB-100 is the first PP2A-inhibitor with a promising safety profile
LB-100 is a small molecule inhibitor of the PP2A phosphatase, a critical enzyme involved in multiple cellular functions.
- Demonstrated safety in 2 phase 1 clinical trials NCT01837667 and NCT03027388
- Documented anti-cancer activity in 25+ publications
- Convenient IV delivery and cost-effective manufacturing
- Good Manufacturing Practice production in place
- FDA: Investigational New Drug (IND) status
- European Medicine Agency: Investigational Medicinal Product Dossier approval Europe in 2022
LB-100:
Mechanism of action in combination with chemotherapy
LB-100 stimulates cell cycle and inhibits DNA repair
This renders cancer cells more susceptible to chemotherapy agents, thus enhancing the treatment's effectiveness.
G1
G0
LB-100M
G2S
Cell Cycle
DNA
Repair
6 | Website | November 20, 2023 |
LB-100:
Mechanism of action in combination with immunotherapy
LB-100 promotes the production of neoantigens and cytokines and enhances T cell proliferation.
This reinforces the systemic immune response to cancer, thus enhancing the effectiveness of immunotherapy.
LB-100
Neoantigen creation
Cytokine production
- cell proliferation
7 | Website | November 20, 2023 |
PP2A inactivating mutations correlate with increased survival in unselected cancers after immunotherapy
8 | Website | November 20, 2023 |
Building a pipeline in multiple cancer indications
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Status | ||
Advanced Soft | Recruiting phase I, 5 sites | |||||
LB-100 | NCT05809830 | activated in Spain. 150 patient | ||||
Tissue Sarcoma | ||||||
+ Chemotherapy | (ASTS) | randomized Phase II planned | ||||
LB-100 | Small Cell Lung | NCT04560972 | Recruiting. Second and third | |||
+ Chemotherapy | Cancer | |||||
+ Immunotherapy | (SCLC) | site added. | ||||
LB-100 | Ovarian Clear Cell | NCT06065462 | IRB approval, opening, GSK | |||
+ Immunotherapy | Cancer | Sponsored | ||||
9 | Website | November 20, 2023 |
LB-100
+ Chemotherapy
Advanced Soft Tissue Sarcoma
NCT05809830
10 | Website | November 20, 2023 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Lixte Biotechnology Holdings Inc. published this content on 20 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 November 2023 21:20:06 UTC.